Table 1.

Characteristics of case–control studies included in XPD Asp312Asn (G312A) polymorphism and breast cancer risk

First author	Year	Country	Ethnicity	Genotyping methods	Source of Control	Cases			Controls
						GG	GA	AA	GG	GA	AA
Hussien	2012	Egypt	Caucasian	ARMS-PCR	HB	12	45	43	25	50	25
Jelonek	2010	Poland	Caucasian	PCR-RFLP	PB	41	59	21	85	123	23
Wang	2010	China	Asian	PCR-RFLP	PB	624	388	220	925	315	193
Crew	2007	USA	Mix	Taqman	PB	415	478	138	490	454	139
Shen	2006	USA	Mix	Taqman	PB	60	80	16	59	64	30
Jorgensen	2007	USA	Mix	Taqman	PB	110	128	22	102	142	29
Debniak	2006	Poland	Caucasian	PCR-RFLP	PB	672	785	269	492	597	173
Mechanic(a)	2006	USA	Caucasian	PCR-RFLP	PB	543	589	130	489	516	128
Mechanic(b)	2006	USA	African-American	PCR-RFLP	PB	564	181	15	517	145	13
Brauch	2004	Germany	Caucasian	PCR-RFLP	PB	347	173	47	276	255	79
Shi	2004	USA	Caucasian	PCR-RFLP	PB	29	32	8	46	27	6
Tang	2002	USA	Mix	PCR-RFLP	PB	52	31	7	74	28	10

PCR-RFLP PCR-restriction fragment length polymorphism, HB hospital based, PB population based